The medical testing giant reported consolidated revenue of ¥114.48 billion for the period, marking a steady rise from the ¥108.58 billion recorded in the previous fiscal year. This growth was mirrored in the company’s core profitability, with operating profit climbing to ¥9.20 billion, up from ¥8.14 billion a year earlier.

Growth Across Key Metrics

The company’s pretax profit reached ¥9.63 billion, a significant improvement over the ¥8.44 billion seen in the same nine-month window last year. According to the financial statement, these results were calculated based on Japanese accounting standards and reflect a period of sustained operational momentum.

Shareholders saw a corresponding boost in value, with basic earnings per share rising to ¥171.47 from ¥134.91. Diluted earnings per share followed a similar trajectory, finishing the period at ¥171.39 compared to ¥134.85 in the prior year. The consistent improvement across all major financial indicators suggests BML Inc. is effectively managing its cost structure while expanding its market footprint in Japan.